Search dm+d | This VMP cannot be matched against our prescribing data.
| Name | Agalsidase beta 35mg powder for solution for infusion vials |
| BNF code | 0908010AEAAABAB |
| Virtual Therapeutic Moiety | Agalsidase beta |
| Date identifier became valid | 9 May 2023 |
| Previous product identifier | 407801001 |
| Basis of preferred name | rINN - Recommended International Non-proprietary |
| Date of name applicability | 13 Jan 2009 |
| Previous name | Agalsidase beta 35mg powder for solution for injection vials |
| Basis of previous name | rINN - Recommended International Non-proprietary |
| Reason for name change | Other |
| Prescribing status | Valid as a prescribable product |
| Sugar free | ✗ |
| Gluten free | ✗ |
| Preservative free | ✗ |
| CFC free | ✗ |
| Dose form | Discrete |
| Unit dose form size | 1.000 |
| Unit dose form units | vial |
| Unit dose unit of measure | vial |
| Virtual Product Ingredient | |
|---|---|
| Ingredient | Agalsidase beta |
| Basis of pharmaceutical strength | Based on Ingredient Substance |
| Strength value numerator | 35.000 |
| Strength value numerator unit | mg |
| Ontology Drug Form & Route | |
| Form & Route | solutioninfusion.intravenous |
| Dose Form | |
| Formulation | Powder for solution for infusion |
| Drug Route | |
| Route | Intravenous |
| Controlled Drug Prescribing Information | |
| Controlled Drug category | No Controlled Drug Status |
| Actual Medicinal Products | |
| Fabrazyme 35mg powder for concentrate for solution for infusion vials (Sanofi) | |
| Virtual Medicinal Product Packs | |
| Agalsidase beta 35mg powder for solution for infusion vials 1 vial | |
dm+d data retrieved from TRUD: release NHSBSA_6.3.0_20250623000001, imported on 24th June 2025 at 16:06:31.